Phase 2 US trials of a single dose of Nurown stem cell treatment from Israel’s Brainstorm on 48 patients suffering from ALS (Lou Gehrig’s disease) showed over 90% efficacy with no adverse effects. Multi-dosage trials can now take place.
(see results of Israeli trials here)
http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=RssLanding&cat=news&id=2186054